EUVIMEDEUVIMED entdecken
Crossref

Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update on Screening and Therapeutic Options

Luis Gabriel de Melo Fernandes, Osório De Castro, Sofia, Sara S. Santos, Gomes Ferreira, Sérgio, Andrade, Luís, Henriques, Cátia

Medicina Interna · 06.12.2023

DOI: 10.24950/rspmi.2522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina Interna, erschienen am 06.12.2023. Verfasst von Luis Gabriel de Melo Fernandes und 9 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common forms of chronic liver disease, particularly associated with obesity and type 2 diabetes mellitus. The prevalence has been increasing in recent years, currently affecting around 25% of the world's population. The hallmark of its pathophysiology lies in insulin resistance and the accumulation of fat inside hepatocytes. Several clinical scores allow cost-effective screening, such as FIB-4 and NFS. Although it is considered the gold standard, liver biopsy can often be avoided by using hepatic elastography. Numerous drugs used in diabetes have therapeutic potential in metabolic dysfunction-associated steatotic liver disease, with the most studied class being GLP-1 receptor agonists. The bidirectional pathophysiological as-sociation between metabolic dysfunction-associated steatotic liver disease and diabetes will enable the development of this field and the emergence of new therapies.

Schlagwörter

non-alcoholic fatty liver diseasescreeningFIB-4hepatic biopsyliver elastographyinsulin resistancehepatic steatosisobesitytype 2 diabetesGLP-1 receptor agonists

Zitieren

APA

Fernandes, L. G. D. M., Castro, O. D., Sofia, Santos, S. S., Ferreira, G., Sérgio, Andrade, Luís, Henriques, & Cátia (2023). Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update on Screening and Therapeutic Options. Medicina Interna. https://doi.org/10.24950/rspmi.2522

Vancouver

Fernandes LGDM, Castro OD, Sofia, Santos SS, Ferreira G, Sérgio, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update on Screening and Therapeutic Options. Medicina Interna. 2023. doi:10.24950/rspmi.2522

BibTeX
@article{Fernandes2023,
  author = {Fernandes, Luis Gabriel de Melo and Castro, Osório De and Sofia and Santos, Sara S. and Ferreira, Gomes and Sérgio and Andrade and Luís and Henriques and Cátia},
  title = {Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update on Screening and Therapeutic Options},
  journal = {Medicina Interna},
  year = {2023},
  doi = {10.24950/rspmi.2522}
}
Kostenlos starten →